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Abstract
The need for stringent temperature control provides significant challenges to pharmaceutical distributors operating in all sectors of the industry.
Products with a frozen storage label requirement can be significantly problematic. This study aimed to provide evidence of robust and repro-
ducible frozen shipment arrangements to be operated by a Phase I clinical trial unit. Dry ice was used to achieve a deep frozen internal parcel
environment and was tested in a laboratory setting using ultra low temperature loggers within dummy product packs within the test parcels. The
laboratory dry ice packing configuration was then repeatedly tested in real time transits using a Glasgow to London delivery schedule. An internal
temperature specification was set to not exceed −10 ◦C during the transport. During each delivery, external temperature monitoring measured the
temperature stress experienced by the box in transit. Results demonstrated the ability of the chosen system to not exceed −13.6 ◦C on average
(−10 ◦C maximum) when exposed to external temperatures of up to +20.1 ◦C (mean kinetic temperature). The effect was maintained for at least
52.5 h.
© 2007 Elsevier B.V. All rights reserved.
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1. Introduction
Clinical trial pharmaceuticals often require low tempera-
ture storage to achieve sufficient stability for an adequate shelf
life. Therefore, frozen stock distribution within Phase I and
II clinical trial networks is relatively common. Indeed, within
the authors’ experience at the Cancer Research UK Formula-
tion Unit (a Phase I production unit), an internal data audit
of clinical trial shipments over 12 months revealed that 23%
of all clinical product transits had a frozen shipment require-
ment.
To maintain product quality, ensure patient safety and treat-
ment efficacy, it is imperative that the distribution of frozen
materials is suitably considered and appropriately handled. In
recently published MHRA data (Taylor et al., 2006), “cold
chain transportation” was listed at 7 in the top 10 trended
deficiencies from UK Good Distribution Practice (GDP, 2007)
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inspections in 2004–2005. This demonstrates both regulatory
interest and the importance of this aspect of pharmaceutical
operations.
‘Dry ice’ is often chosen for frozen transits. The material’s
common nomenclature is derived from the ability to sublime to
carbon dioxide gas. Thus, the internal parcel environment does
not become ‘wet,’ a factor for consideration in pharmaceutical
transport. Exceptionally low temperatures can be achieved dur-
ing the transit with a sublimation temperature of −78.5 ◦C (Lide,
2006). Dry ice would be expected to maintain frozen conditions
for as long as it persists, a time course influenced by the amount
used, transit duration and external temperature (or heat stress)
experienced during the shipment. These represent measurable
test parameters that would contribute to a transit verification
study.
The aim of this study was to firstly determine, and
then to repeatedly test, appropriate transit arrangements for
frozen clinical trial products using dry ice. These tests
would be used to determine robust and reproducible frozen
shipment arrangements to be operated by our Phase I
unit.
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2. Materials and methods
2.1. Transit container
An expanded polystyrene transit container enclosed in
white cardboard (Product code CL87-30 from Cool Logistics,
Soulbury, UK) was used in all studies. External dimen-
sions were 45 cm × 45 cm × 43 cm, with internal dimensions
32 cm × 32cm × 29.5 cm.
2.2. Dry ice
Single blocks of dry ice (BOC, Manchester, UK) were
obtained from the University of Strathclyde Chemistry Stores.
Dry ice weight was determined before and after each test using a
34-kg top pan balance (Model LA34000 from Sartorius, Epsom,
UK).
2.3. External temperature logging devices
External temperature was monitored at 30-min intervals using
a single Sergeant Temp Version 5 temperature logger (Wessex
Power Technology, Poole, UK). The temperature logger was
bubble wrapped for transit protection and placed in a moulded
recess in the exterior face of the transit container lid. At test con-
clusions, logging was stopped by data download from the device.
Data were graphed and analysed using the logging device soft-
ware program. Measurement capability is in the range −40 to
+70 ◦C with accuracy to ±0.5 ◦C. The supplier company pro-
vides annual re-calibration and certification.
2.4. Internal temperature logging devices
Internal parcel temperature was monitored at 34-s intervals
using Marathon Products edl-CO2 ultra low temperature loggers
(Wessex Power Technology, Poole, UK). At test conclusions,
logging was stopped by data download from the device. Data
were graphed and analysed using the logging device software
program. Measurement capability is in the range −81 to +30 ◦C
with accuracy to ±0.2 ◦C at 0◦C, and ±2.5 ◦C at extremes. The
supplier company provides annual re-calibration and certifica-
tion.
2.5. Dummy product packs
Eight 132 mm × 132 mm × 50 mm white cardboard vial
boxes with removable lids were used as dummy product packs
(PakGen, Sevenoaks, UK). Three boxes of the eight carried an
edl-CO2 temperature logging device with their internal card
dividers removed to allow inclusion of the logger. All boxes
used were empty of vial product with the intent of monitoring
the surrounding environment that vials would experience, and
not of the internal environment of individual vials.
For laboratory testing only, three dummy pack boxes were
stacked three high in what was described as a ‘tower’ box
arrangement. Each box had a temperature logger enclosed. The
Fig. 1. ‘Flat’ box packing arrangement in the standard insulated transit container.
Position 1 is the top box layer (with one edl-CO2 logger), position 2 the lower
box layer (with two edl-CO2 loggers) and position 3 is the dry ice block. Box
layers were bagged and bubble wrapped for transit protection.
tower was bubble wrapped and then placed in the transit con-
tainer.
For some laboratory and all transit tests, eight dummy pack
boxes were packed in two layers with four boxes in each, stacked
two high in what was described as a ‘flat’ box arrangement
(Fig. 1). The base box layer had a temperature logger in oppo-
site corners of the square created by the four box arrangement
(loggers 2 and 3). The top layer had a temperature logger in
one of the four corners placed directly over a lower layer logger
position (logger 1). Before placement into the transit container,
each layer of boxes was first wrapped in a grip seal bag (four
boxes per bag), then outer bubble wrapped as per Unit proto-
col for protection during transit. Polystyrene chips took up the
remaining space to reduce excessive movement of the contents
during transit.
2.6. Laboratory tests
Laboratory tests firstly determined the minimum temperature
achieved by placing edl-CO2 temperature loggers in direct con-
tact with the dry ice block on the base of a transit container.
Further laboratory tests determined the temperatures recorded
by loggers placed within dummy packs in both ‘tower’ and ‘flat’
box packaging arrangements.
2.7. Shipping tests
The transit container was packaged with dry ice, dummy
packs in a ‘flat’ box arrangement and temperature loggers as pre-
viously described. The whole transit container was then brown
paper wrapped and red labeled to identify a temperature trial
in progress and to warn the recipient not to open the package.
Transits were made in standard, non-refrigerated vehicles using
a Glasgow to London return route.
3. Results
Laboratory tests recorded temperatures of −61.4 ◦C when
loggers were placed in direct contact with the ice block. Intro-
duction of loggers within dummy product packs produced some
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Table 1
Results from internal parcel temperature monitoring for laboratory based tests using different packaging configurations
Direct contact
with dry ice (◦C)
Tower box
arrangement (◦C)
Flat box
arrangement (◦C)
Logger 1a −53.6 −10.1b −21.9c
Logger 2a −57.8 −24.6c −48.9d
Logger 3a −61.4 −44.7d −42.2d
Dry ice weight at study start 8.795 kg 8.723 kg 9.601 kg
One block of dry ice was used in each test.
a edl-CO2 ultra low temperature data logger. Temperatures noted are average over the period of study.
b Top position.
c Middle position.
d Base position (all with respect to the parcel base).
Table 2
Results from internal parcel temperature monitoring for transit tests using the ‘flat’ box packaging configuration
Test 1 in ◦C (avg./max.) Test 2 in ◦C (avg./max.) Test 3 in ◦C (avg./max.) Test 4 in ◦C (avg./max.) Test 5 in ◦C (avg./max.)
Logger 1a,b −30.2/−20.3 −20.7/−12.2 −23.3/−11.3 −21.5/−17.2 −13.6/−10.0
Logger 2a,c −51.9/−41.8 −34.8/−10.7 −41.4/−29.4 −44.6/−31.7 −36.5/−30.42
Logger 3a,c −50.4/−42.8 −41.8/−23.3 −38.5/−24.7 −47.6/−33.8 −38.9/−33.6
Exteriord +11.4 +13.2 +10.9 +20.1 +13.4
Dry ice at study start 7.864 kg 8.482 kg 9.319 kg 8.358 kg 8.174 kg
One block of dry ice was used in each test.
a edl-CO2 ultra low temperature logger.
b Top layer.
c Base layer (with respect to the parcel base).
d Sergeant Temp temperature logger (mean kinetic temperature is presented).
insulating effects, with the recorded value rising to −48.9 ◦C.
Not surprisingly, box positioning had an effect. Increased dis-
tance from the dry ice block increased the average recorded
temperatures in the ‘tower’ box arrangement. It was con-
cluded that ‘flat’ box packing would be used in real time
transits, as the maximum average temperatures were lower than
in the stacked ‘tower’ box arrangement (Table 1, −48.9 to
−21.9 ◦C in the former case, −44.7 to −10.1 ◦C in the lat-
ter).
Transit tests were all successfully completed and were
compliant with the nominal specification of individual inter-
nal temperatures not exceeding a maximum −10 ◦C during
transport (Table 2 and Fig. 2). “Dips” in temperature were rou-
tinely observed co-incident in Fig. 2 with very early morning
(approximately 03.00–07.00) or late evening (approximately
21.30–02.00), suggested times of minimum parcel handling or
road transit disturbance.
The single block of dry ice used in each test had weight in
the range 7.864–9.319 kg. In all transit tests, not more than 5 kg
of the ice had been consumed during a maximum of 52.5 h in
transit (Table 3).
The ‘stress’ exerted on the parcel was recorded by external
parcel temperature monitoring. To allow interpretation of nor-
mal fluctuating day and night temperatures, the mean kinetic
external temperature of each transit was calculated. All transit
tests were carried out in summer to provide maximum exter-
nal seasonal temperature. Interestingly, during these summer
tests one transit in particular (Test 4 in Table 2) was sent out
during a period of un-seasonally high temperatures recorded in
Glasgow and London with readings regularly in the high 20 ◦C
range for Glasgow, and in excess of 30 ◦C for London (July
2006). Although mean kinetic temperatures ranged from +10.9
to +20.1 ◦C, dry ice sublimation rate (approximated from the
used dry ice weight divided by transit time) was relatively con-
stant ranging from 0.076 to 0.096 kg/h, equivalent to an overall
average rate of 0.085 kg/h (±0.007 kg/h).
Fig. 2. Test 4 temperature data covering a Glasgow to London return transit with
external mean kinetic temperature of +20.1 ◦C. External temperature data are
shown as - - -, internal temperature data for an upper layer box as · · ·, internal
temperature data for two lower layer boxes as — — — and ——. Forty-eight
hours of data are shown, starting at 14.30 h.
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Table 3
Approximate dry ice sublimation rates for the parcels under test (the test numbers correlate to Table 2 results)
Test 1 Test 2 Test 3 Test 4 Test 5
Dry ice used during transit 4.256 kg 4.519 kg 4.353 kg 4.725 kg 3.983 kg
Total duration of transit test 51 h 52 h 51 h 49 h 52.5 h
Approx. rate of sublimation 0.083 kg/h 0.087 kg/h 0.085 kg/h 0.096 kg/h 0.076 kg/h
4. Discussion
We have previously reported on the importance of cold chain
product management (Elliott and Halbert, 2005) where transit
conditions that can affect product stability and therefore effi-
cacy and patient safety, or have financial penalty if a product
is rejected, were all discussed. In frozen product transport, the
patient safety risks are certainly equivalent, if not higher, as
frozen materials too will potentially suffer detriment to product
quality following any significant out of specification temperature
excursions.
The complexity of the verification studies needed for assess-
ment of shipping conditions may be linked to both the type of
product and to the distribution network in which it is destined to
travel. Global distribution with multipart and intricate networks
undoubtedly will attract more difficulties than a straight ‘A to B’
overnight land based delivery. Nonetheless, the aim is the same
as summarized by Ennis, 2006, in that the clinical trial product
received by a pharmacy for patient dosing should be exactly of
the same quality as that certified by the manufacturer’s Qualified
Person (QP).
In this study, we sought straightforward, robust and repeat-
able frozen shipping conditions for UK based delivery that
would be within the operational capabilities of a small Phase
I clinical trial distribution network. The system chosen, often
described as ‘passive’ as there is a simple reliance on dry ice for
deep frozen internal parcel conditions, has been shown to sat-
isfy all of these aims. Internal parcel temperatures did not rise
above the specification of not greater than −10 ◦C, and indeed
on average were often much lower. Conditions were maintained
for the duration of an overnight delivery and beyond, in fact
up to 52.5 h providing a significant time contingency for stray
deliveries. Repeatability was shown in five individual real time
transit tests, all of which were stressed by monitored external
summer temperatures.
In summary, the frozen transit conditions selected have shown
satisfactory real time shipment performance in terms of robust-
ness and repeatability, were straightforward in terms of operator
training and were cost effective. More importantly, the system
was able to provide temporary storage conditions that would
ensure suitability for product use on arrival at the destination, a
process that is designed to ultimately protect patients on clinical
trials.
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